Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Seretide for obstructive lung disease.

Kenneth R Chapman1

  • 1Asthma Centre and Pulmonary Rehabilitation Program, Toronto Western Hospital, University Health Network, Suite 4-011 ECW, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada. kchapman@ca.inter.net

Expert Opinion on Pharmacotherapy
|February 28, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term Efficacy of Dupilumab Versus Tezepelumab in Asthma: A Matching-Adjusted Indirect Comparison.

The journal of allergy and clinical immunology. In practice·2026
Same author

Effects of rostral fluid shift on small airway narrowing in asthma before and after bronchodilation.

Sleep & breathing = Schlaf & Atmung·2026
Same author

Characteristics of bronchiectasis in patients with different genotypes of severe α<sub>1</sub>-antitrypsin deficiency from the EARCO registry.

ERJ open research·2026
Same author

Routine Blood Biomarkers in Patients With the PI*SZ Genotype of Alpha-1 Antitrypsin Deficiency: Data From the EARCO Registry.

Archivos de bronconeumologia·2026
Same author

Transient early blood eosinophil increases do not affect dupilumab's long-term efficacy in patients with moderate-to-severe asthma.

The Journal of allergy and clinical immunology·2025
Same author

Clinically important deterioration in a mild-moderate COPD population.

ERJ open research·2025

Seretide, a combination inhaler for obstructive airways disease, is effective for moderate-to-severe asthma, improving lung function and reducing exacerbations. It offers convenience and potential benefits for chronic obstructive pulmonary disease (COPD) patients.

Area of Science:

  • Respiratory Medicine
  • Pharmacology

Background:

  • Obstructive airways diseases, including asthma and chronic obstructive pulmonary disease (COPD), are increasingly prevalent.
  • Seretide (Advair) is a combination inhaler containing salmeterol (long-acting beta2-agonist) and fluticasone propionate (inhaled corticosteroid).

Purpose of the Study:

  • To evaluate the efficacy and role of Seretide in the maintenance therapy of obstructive airways diseases.
  • To assess its effectiveness in asthma and its potential in COPD management.

Main Methods:

  • Review of clinical studies on Seretide in pediatric and adult populations with persistent asthma.
  • Examination of data regarding salmeterol and fluticasone propionate in COPD patients.

Main Results:

Related Experiment Videos

  • Seretide is at least equivalent to separate component administration and superior to monotherapy in moderate-to-severe asthma.
  • The combination improves lung function, symptom scores, quality of life, and reduces exacerbation rates.
  • Salmeterol is an effective bronchodilator, and fluticasone reduces exacerbations in COPD.

    • Conclusions:

    • Seretide is a valuable option for moderate-to-severe persistent asthma, offering convenience and improved compliance.
    • It shows promise in the management of COPD, with ongoing clinical trials.
    • The combination therapy represents a significant advancement in managing common obstructive lung diseases.